Skip to main content
. 2019 May 13;12:1257–1264. doi: 10.2147/IDR.S197735

Table 3.

Analysis of 14-day mortality with unadjusted and adjusted cox proportional hazards regression model

Deaths (%) Survivors (%) Unadjusted Adjusted
n=60 n=508 Mortality rate ratio (95% CI) P-value Mortality rate ratio (95% CI) P-value(P<0.05 in bold)
Age [median (25–75 percentiles)] 74 (66–84) 71 (61–84) 1.01 (0.99–1.03) 0.26
Gender (female) 29 (48.3) 289 (56.9) 0.71 (0.41–1.21) 0.22
Acquisition (n=503)
Community-acquired 21 (39.6) 290 (64.4) 1.00 1.00
Health care related 20 (37.7) 90 (20.0) 3.07 (1.59–5.92) <0.01 3.39 (1.77–6.49) <0.01
Hospital-acquired 12 (22.6) 70 (15.6) 2.37 (1.11–5.04) 0.03 2.17 (1.02–4.62) <0.05
Charlson Comorbidity Index
Low 11 (18.3) 146 (28.7) 1.00 1.00
Medium 21 (35.0) 186 (36.6) 1.50 (0.70–3.21) 0.30 1.47 (0.65–3.32) 0.35
High 28 (46.7) 176 (34.6) 2.11 (1.02–4.39) <0.05 1.93 (1.05–3.53) 0.06
Intensive care unit 3 (5.0) 3 (0.6) 8.87 (1.75–44.93) 0.02 20.45 (5.31–78.82) <0.01
Intervention hospital 14 (23.3) 161 (31.7) 0.66 (0.35–1.23) 0.24 0.60 (0.32–1.59) 0.15
Polymicrobial bacteraemia (n=503) 2 (3.3) 14 (2.8) 1.05 (0.24–4.72) 1.00 1.75 (0.50–6.05) 0.35
Resistant strain 17 (28.3) 94 (18.5) 1.31 (0.49–3.49) 0.58
Combination with gentamicin 8 (13.3) 75 (14.8) 0.88 (0.41–1.95) 1.00
Combination with ciprofloxacin 25 (41.7) 150 (29.5) 1.71 (0.99–2.95) 0.08 2.14 (0.98–4.68) 0.04
Treatment with cefuroxime 45 (75.0) 332 (65.4) 1.59 (0.86–2.93) 0.15 3.95 (1.12–13.90) 0.02

Note: P<0.05 shown in bold.